Cargando…

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

BACKGROUND: The efficacy, safety and tolerability of lumiracoxib, a novel selective cyclooxygenase-2 (COX-2) inhibitor, has been demonstrated in previous studies of patients with osteoarthritis (OA). As it is important to establish the long-term safety and efficacy of treatments for a chronic diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy, Tannenbaum, Hyman, Patel, Neha P, Notter, Marianne, Sallstig, Peter, Reginster, Jean-Yves
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2322990/
https://www.ncbi.nlm.nih.gov/pubmed/18328090
http://dx.doi.org/10.1186/1471-2474-9-32
_version_ 1782152609490010112
author Fleischmann, Roy
Tannenbaum, Hyman
Patel, Neha P
Notter, Marianne
Sallstig, Peter
Reginster, Jean-Yves
author_facet Fleischmann, Roy
Tannenbaum, Hyman
Patel, Neha P
Notter, Marianne
Sallstig, Peter
Reginster, Jean-Yves
author_sort Fleischmann, Roy
collection PubMed
description BACKGROUND: The efficacy, safety and tolerability of lumiracoxib, a novel selective cyclooxygenase-2 (COX-2) inhibitor, has been demonstrated in previous studies of patients with osteoarthritis (OA). As it is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA, the present study compared the effects of lumiracoxib at doses of 100 mg once daily (o.d.) and 100 mg twice daily (b.i.d.) with those of celecoxib 200 mg o.d. on retention on treatment over 1 year. METHODS: In this 52-week, multicentre, randomised, double-blind, parallel-group study, male and female patients (aged at least 40 years) with symptomatic primary OA of the hip, knee, hand or spine were randomised (1:2:1) to lumiracoxib 100 mg o.d. (n = 755), lumiracoxib 100 mg b.i.d. (n = 1,519) or celecoxib 200 mg o.d. (n = 758). The primary objective of the study was to demonstrate non-inferiority of lumiracoxib at either dose compared with celecoxib 200 mg o.d. with respect to the 1-year retention on treatment rate. Secondary outcome variables included OA pain in the target joint, patient's and physician's global assessments of disease activity, Short Arthritis assessment Scale (SAS) total score, rescue medication use, and safety and tolerability. RESULTS: Retention rates at 1 year were similar for the lumiracoxib 100 mg o.d., lumiracoxib 100 mg b.i.d. and celecoxib 200 mg o.d. groups (46.9% vs 47.5% vs 45.3%, respectively). It was demonstrated that retention on treatment with lumiracoxib at either dose was non-inferior to celecoxib 200 mg o.d. Similarly, Kaplan-Meier curves for the probability of premature discontinuation from the study for any reason were similar across the treatment groups. All three treatments generally yielded comparable results for the secondary efficacy variables and all treatments were well tolerated. CONCLUSION: Long-term treatment with lumiracoxib 100 mg o.d., the recommended dose for OA, was as effective and well tolerated as celecoxib 200 mg o.d. in patients with OA. TRIAL REGISTRATION: clinicaltrials.gov NCT00145301
format Text
id pubmed-2322990
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-23229902008-04-18 Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis Fleischmann, Roy Tannenbaum, Hyman Patel, Neha P Notter, Marianne Sallstig, Peter Reginster, Jean-Yves BMC Musculoskelet Disord Research Article BACKGROUND: The efficacy, safety and tolerability of lumiracoxib, a novel selective cyclooxygenase-2 (COX-2) inhibitor, has been demonstrated in previous studies of patients with osteoarthritis (OA). As it is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA, the present study compared the effects of lumiracoxib at doses of 100 mg once daily (o.d.) and 100 mg twice daily (b.i.d.) with those of celecoxib 200 mg o.d. on retention on treatment over 1 year. METHODS: In this 52-week, multicentre, randomised, double-blind, parallel-group study, male and female patients (aged at least 40 years) with symptomatic primary OA of the hip, knee, hand or spine were randomised (1:2:1) to lumiracoxib 100 mg o.d. (n = 755), lumiracoxib 100 mg b.i.d. (n = 1,519) or celecoxib 200 mg o.d. (n = 758). The primary objective of the study was to demonstrate non-inferiority of lumiracoxib at either dose compared with celecoxib 200 mg o.d. with respect to the 1-year retention on treatment rate. Secondary outcome variables included OA pain in the target joint, patient's and physician's global assessments of disease activity, Short Arthritis assessment Scale (SAS) total score, rescue medication use, and safety and tolerability. RESULTS: Retention rates at 1 year were similar for the lumiracoxib 100 mg o.d., lumiracoxib 100 mg b.i.d. and celecoxib 200 mg o.d. groups (46.9% vs 47.5% vs 45.3%, respectively). It was demonstrated that retention on treatment with lumiracoxib at either dose was non-inferior to celecoxib 200 mg o.d. Similarly, Kaplan-Meier curves for the probability of premature discontinuation from the study for any reason were similar across the treatment groups. All three treatments generally yielded comparable results for the secondary efficacy variables and all treatments were well tolerated. CONCLUSION: Long-term treatment with lumiracoxib 100 mg o.d., the recommended dose for OA, was as effective and well tolerated as celecoxib 200 mg o.d. in patients with OA. TRIAL REGISTRATION: clinicaltrials.gov NCT00145301 BioMed Central 2008-03-07 /pmc/articles/PMC2322990/ /pubmed/18328090 http://dx.doi.org/10.1186/1471-2474-9-32 Text en Copyright © 2008 Fleischmann et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Fleischmann, Roy
Tannenbaum, Hyman
Patel, Neha P
Notter, Marianne
Sallstig, Peter
Reginster, Jean-Yves
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
title Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
title_full Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
title_fullStr Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
title_full_unstemmed Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
title_short Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
title_sort long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2322990/
https://www.ncbi.nlm.nih.gov/pubmed/18328090
http://dx.doi.org/10.1186/1471-2474-9-32
work_keys_str_mv AT fleischmannroy longtermretentionontreatmentwithlumiracoxib100mgonceortwicedailycomparedwithcelecoxib200mgoncedailyarandomisedcontrolledtrialinpatientswithosteoarthritis
AT tannenbaumhyman longtermretentionontreatmentwithlumiracoxib100mgonceortwicedailycomparedwithcelecoxib200mgoncedailyarandomisedcontrolledtrialinpatientswithosteoarthritis
AT patelnehap longtermretentionontreatmentwithlumiracoxib100mgonceortwicedailycomparedwithcelecoxib200mgoncedailyarandomisedcontrolledtrialinpatientswithosteoarthritis
AT nottermarianne longtermretentionontreatmentwithlumiracoxib100mgonceortwicedailycomparedwithcelecoxib200mgoncedailyarandomisedcontrolledtrialinpatientswithosteoarthritis
AT sallstigpeter longtermretentionontreatmentwithlumiracoxib100mgonceortwicedailycomparedwithcelecoxib200mgoncedailyarandomisedcontrolledtrialinpatientswithosteoarthritis
AT reginsterjeanyves longtermretentionontreatmentwithlumiracoxib100mgonceortwicedailycomparedwithcelecoxib200mgoncedailyarandomisedcontrolledtrialinpatientswithosteoarthritis